Lv5
1098 积分 2024-04-18 加入
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
1天前
已完结
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
2天前
已完结
Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non–Small-Cell Lung Cancer With EGFR Mutation (IMPACT)
2天前
已完结
Evolving roles of MET as a therapeutic target in NSCLC and beyond
10天前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR -Mutated Advanced NSCLC
25天前
已完结
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
1个月前
已完结
ROS1 Fusions in Cancer: A Review
1个月前
已完结
ROS1 Fusions in Cancer: A Review
1个月前
已关闭
RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges
1个月前
已完结
Rapid Advances in Resectable Non–Small Cell Lung Cancer
1个月前
已完结
皖公网安备34019202002308
